Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Emcure launches...

    Emcure launches generic Eribulin at 40 percent lower price in India

    Farhat NasimWritten by Farhat Nasim Published On 2019-04-04T09:30:06+05:30  |  Updated On 16 Aug 2021 2:41 PM IST

    Emcure Pharmaceuticals will manufacture Eribulin at its plant at Hinjewadi in Pune and market it at a cost which will be approximately 40 per cent less than the innovator brand.


    New Delhi: Drug firm Emcure Pharmaceuticals Wednesday said it has launched generic metastatic breast cancer treatment drug under the brand name 'Eribulin' in India. The product is a generic version of Eisai Pharmaceutical's cancer drug sold under the brand name, Halaven, Emcure Pharmaceuticals said in a statement.


    "Breast cancer is the most common type of cancer affecting women in India and its incidence is on the rise. Currently, available treatment for triple negative breast cancer in India is out of reach of most patients due to its high cost," the company's Business Strategy & Specialty Business President Sainath Iyer said.


    Read Also: NPPA fixes retail price of Emcure pharma's HIV drug


    The company's Eribulin will change this scenario by offering the drug at a reasonable price to the patients in India, he added.


    The company will manufacture the product at its plant at Hinjewadi in Pune and market it at a cost which will be approximately 40 per cent less than the innovator brand, the company said.


    "The drug would currently be marketed in India, however, Emcure plans to register the brand in international markets as well, wherever the drug is about to go off-patent," the company said.


    The company currently has the presence in oncology, nephrology, antiretroviral, gynaecology, cardiac, anti-malarial and anti-infective therapies segments.


    Also Read: Sun Pharma, Emcure, Dr Reddys added in US price-fixing probe
    anti infective therapiesanti-malarialantiretroviralbreast cancerbreast cancer drugcancercancer drugcardiacEisai PharmaceuticalsEmcureemcure pharmaceuticalsEmcures EribulinEribulingeneric metastaticgeneric versiongynaecologyhealthHealthcareHinjewadiIndianephrologyoncologypharmapharma newspharma news india
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok